ASH 2023 | Prof. Fengkui Zhang and Prof. Bing Han Team: KP104 Effectively Controls Intravascular and Extravascular Hemolysis in PNH Patients Without Complement Inhibitor Treatment
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and life-threatening blood disorder. Due to the complexity of complement biology and various pathogenic pathways, there remains a significant unmet clinical need, urgently requiring next-generation drugs with superior efficacy and dosing convenience compared to current therapies. At the recently held 65th American Society of Hematology (ASH) Annual Meeting, Prof. Fengkui Zhang from the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology) and Prof. Bing Han's team from Peking Union Medical College Hospital presented an oral report (Abstract: 572). The study explored the safety and effectiveness of the dual-function C5 antibody/H factor fusion protein KP104 in PNH patients who had not received complement inhibitor treatment. This research brings hope to address this challenging issue and has been selected as a highlight of "ASH 2024." The summarized details are presented below in this issue of "Hematology Insight."